Neurological disease

Neuropsychiatric diseaseMental illness represents the leading cause of disability burden in Australia. Given an ageing population and the ongoing demands of the modern lifestyle, the incidence of neurodegenerative and neuropsychiatric disease is on the rise.

Unfortunately, the attrition rate associated with novel drug discovery for central nervous system (CNS) disorders is unacceptably high. This reflects the difficulty in understanding and treating neurodegenerative and neuropsychiatric diseases, including schizophrenia, anxiety and depression, which are complex and polygenic in nature.

Studies at DDB focus on understanding how modulation of G protein-coupled receptor targets in the CNS can provide new insights into mechanisms underlying neurological disease — in particular deficits associated with schizophrenia — and identify novel therapeutic modalities.

.

Research laboratories

Analytical & Structural Neuropharmacology Cancer & Neural-Immune Regulation
 
Dr Celine Valant Dr David Thal Prof Arthur Christopoulos   A/Prof Erica Sloan
Cellular & Molecular Metabolism Endocrine & Neuropharmacology
 
Prof Mark Febbraio     Dr Katie Leach Dr Karen Gregory
Integrated Neurogenic Mechanisms Metabolic GPCR Biology
 
Dr Simona Carbone Dr Daniel Poole Dr Nicholas Veldhuis   Prof Patrick Sexton A/Prof Denise Wootten
Molecular & Translational Drug DiscoverySpatial Organisation of SignallingStem Cell Biology
Dr Christopher Langmead Dr Michelle Halls Dr John Haynes